BDX (Becton Dickinson) ROCE % : 4.38% (As of Mar. 2025)

View and export this data going back to 1963. Start your Free Trial

What is Becton Dickinson ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Becton Dickinson's annualized ROCE % for the quarter that ended in Mar. 2025 was 4.38%.

Becton Dickinson ROCE % Historical Data

The historical data trend for Becton Dickinson's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Becton Dickinson ROCE % Chart

Becton Dickinson Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

ROCE %

Get a 7-Day Free Trial

2.00

4.53

4.72

4.63

5.36

Becton Dickinson Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial															6.62	5.32	5.50	3.87	4.38

Becton Dickinson ROCE % Calculation

Becton Dickinson's annualized ROCE % for the fiscal year that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	2533	/	( ( (52780 - 6641)	+	(57286 - 8956) )	/ 2 )
	=	2533	/	( (46139	+	48330)	/ 2 )
	=	2533	/	47234.5
	=	5.36 %

Becton Dickinson's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	2056	/	( ( (54665 - 7664)	+	(54467 - 7691) )	/ 2 )
	=	2056	/	( ( 47001	+	46776 )	/ 2 )
	=	2056	/	46888.5
	=	4.38 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

Becton Dickinson (NYSE:BDX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Becton Dickinson ROCE % Related Terms

Thank you for viewing the detailed overview of Becton Dickinson's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Becton Dickinson Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Becton Dickinson & Co (NYSE:BDX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BDX:Mexico 1BDX:Italy 0R19:UK BOX:Germany BOX:Germany BOX:Germany B1DX34:Brazil BDX:Austria

Address

1 Becton Drive, Franklin Lakes, NJ, USA, 07417-1880

Website

https://www.bd.com

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.

Executives

Michael David Garrison	officer: EVP and President Medical	BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Richard Byrd	officer: EVP & President Interventional	BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Bertram L Scott	director	C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Jeffrey William Henderson	director	7000 CARDINAL PLACE, DUBLIN OH 43017
David Shan	officer: EVP, Integrated Supply Chain	1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Shana Carol Neal	officer: Chief People Officer	9120 LOCKWOOD BOULEVARD, MECHANICSVILLE VA 23116
Roland Goette	officer: EVP and President, EMEA	BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Thomas J Spoerel	officer: VP Controller & Chief Acct Off	BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Claire Fraser	director	C/O BECTON, DICKINSON AND COMPANY, FRANKLIN LAKES NJ 07465
David Hickey	officer: EVP & President, Life Sciences	BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Joanne Waldstreicher	director	C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD, SUITE 223, SOUTH SAN FRANCISCO CA 94080
Michelle Quinn	officer: EVP and Acting General Counsel	1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Christopher Delorefice	officer: EVP & CFO	BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Polen Thomas E Jr	officer: Executive Vice President	BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Samrat S. Khichi	officer: EVP and General Counsel	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873